文献速递糖尿病

先天性高胰岛素性低血糖症伴新HADH突变及胰腺GLP-1受体过表达

Congenital Hyperinsulinemic Hypoglycemia With a New HADH Mutation and Pancreatic Overexpression of GLP-1 Receptors.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

报告两名近亲结婚患者携带新HADH基因纯合突变(c.796G>T)导致先天性高胰岛素性低血糖症,随访超过30年。二氮嗪初始稳定病情,成年后加用生长抑素类似物成功控制低血糖,68Ga-DOTA-exendin PET/CT显示全胰腺摄取增加。

要点

  • 两名近亲患者新生儿期诊断CHH,携带HADH基因新纯合突变c.796G>T。
  • 血酰基肉碱谱显示丁酰肉碱升高,符合HADH酶功能障碍。
  • 68Ga-DOTA-exendin PET/CT显示两名患者全胰腺GLP-1受体摄取增加。

核心结论

  • 临床表现、生化检查及对二氮嗪和生长抑素类似物的治疗反应与既往HADH突变报道一致。
  • 胰腺GLP-1受体过表达在此背景下值得进一步研究。

研究设计与样本

  • 病例报告,纳入两名近亲结婚的CHH患者,随访超过30年。
  • 采用NextSeq 500测序检测ABCC8、HADH和KCNJ11等常染色体隐性遗传已知基因。
  • 测定酰基肉碱谱并进行68Ga-DOTA-exendin PET/CT检查。

主要发现

  • 两名患者均在新生儿期诊断CHH,初始二氮嗪治疗使病情稳定。
  • 随年龄增长,低血糖事件增多且碳水化合物摄入增加,导致两名患者均出现肥胖。
  • 成年后加用生长抑素类似物成功控制低血糖。
  • 基因分析发现HADH基因新纯合突变c.796G>T。
  • 酰基肉碱谱显示血浆丁酰肉碱升高,符合HADH酶功能障碍;68Ga-DOTA-exendin显示两名患者全胰腺摄取增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The most common cause of endogenous hyperinsulinemic hypoglycemia in neonates [congenital hyperinsulinemic hypoglycemia (CHH)] is different monogenic forms of gene mutations. About 50% of the mutations are known. We present a new mutation within the short-chain L-3-hydroxyacyl-CoA dehydrogenase (HADH) gene causing CHH in 2 related patients. METHODS: The course of 2 consanguineous patients with CHH are presented with a follow-up of >30 years. NextSeq 500 sequencing was performed and confined on known genes with autosomal recessive inheritance, namely ABCC8 (MANE Select: NM_00352.6), HADH (MANE Select: NM_005327.7), and KCNJ11 (MANE Select: NM_00525.4). Acylcarnitine profiles were measured and 68Ga-DOTA exendin positron emission tomography/computer tomography was performed. RESULTS: CHH was diagnosed in both patients in the neonatal period. A therapy with diazoxid was initiated, which initially stabilized the disease in both children. With advancing age, more hypoglycemic events occurred with an increase in carbohydrate intake, leading to obesity in both patients. In addition to diazoxide, somatostatin analogues were successfully added in adulthood. A genetic analysis documented a new homozygote mutation in the HADH gene (HADH-variant c.796G > T). An acylcarnitine profile showed an increased plasma butyryl-carnitine, consistent with a dysfunction of the HADH enzyme. 68Gallium-DOTA-exendin showed an increased uptake in the whole pancreas in both patients. CONCLUSION: Clinical presentation, biochemical workup, and therapeutical response to diazoxide and somatostatin analogues are consistent with previous reports of HADH mutations. The overexpression of glucagon-like peptide 1 receptors in this context warrants further research.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Widmer A, Zumsteg U, Szinnai G, et al. Congenital Hyperinsulinemic Hypoglycemia With a New HADH Mutation and Pancreatic Overexpression of GLP-1 Receptors. J Clin Endocrinol Metab. 2026. PMID: 40705962. doi:10.1210/clinem/dgaf423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。